---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028908"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:19:25.574611+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q3 net loss $70.3M; GSK ends collaboration; LYL797 data delayed to H1 2024

## Summary
- Net loss $70.3M vs $48.9M YoY; non-GAAP net loss $43.7M vs $35.7M.
- Cash $750.7M as of Sep 30, 2022; funding extends into 2026.
- GSK terminates NY-ESO-1 programs LYL132/LYL331 effective Dec 24, 2022; not due to safety/efficacy.
- IND cleared for LYL845 TIL therapy; initial data expected 2024.
- LYL797 enrollment slower; initial data now expected first half of 2024.

## SEC filing metadata
- accession: 0001628280-22-028908
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/lyel-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028908
- JSON: https://secwatch.observer/filing/0001628280-22-028908.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028908.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported financial results for third quarter of 2022.
  - Period: third quarter of 2022
  - Result: reported results
  source text: On November 8, 2022, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.